{
    "Trade/Device Name(s)": [
        "VIDAS\u00ae D-Dimer Exclusion II Assay",
        "D-Dimer Exclusion II Assay"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K112818",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040882"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DAP"
    ],
    "Summary Letter Date": "July 30, 2012",
    "Summary Letter Received Date": "July 31, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7320"
    ],
    "Regulation Name(s)": [
        "Fibrinogen/fibrin degradation products assay"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Fibrin degradation products (FbDP)",
        "D-Dimer"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Sodium citrate tube",
        "CTAD tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VIDAS family instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked fluorescent assay (ELFA)",
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [
        "Immunoenzymatic determination",
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS D-Dimer Exclusion II automated quantitative immunoenzymatic assay for plasma FbDP using ELFA on VIDAS instruments",
    "Indications for Use Summary": "Automated quantitative test on VIDAS instruments for immunoenzymatic determination of fibrin degradation products in human plasma to aid in excluding DVT and PE in outpatients when used with a clinical pretest probability assessment model",
    "fda_folder": "Hematology"
}